SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Illustration of two people talking, trying to connect
Career Advice
Manager’s Toolbox: How to Have Difficult Conversations
Having difficult conversations with the right mindset can build trust and further develop your relationship with your team.
September 4, 2024
 · 
6 min read
 · 
Bruce Wu
Illustration of manager in tug of war
Management
Stuck in the Middle: How Millennial Managers Can Bridge Generational Gaps
Getting caught between younger team members and older bosses can be stressful for millennial managers. A leadership expert and millennial manager share tips for bridging the gap between these groups.
September 4, 2024
 · 
4 min read
 · 
Angela Gabriel
Podcast
Lilly’s DTC Obesity Push, Layoffs, and an Eye on Ocular Diseases
Eli Lilly offers weight loss drug Zepbound directly to consumers while Novo Nordisk continues to struggle with supply challenges for its own GLP-1s. Meanwhile, gene therapies for retinal diseases target competitive market, and layoffs persist.
September 4, 2024
 · 
1 min read
 · 
Heather McKenzie
Illustration of a stack of paper and tweezers editing a strand of DNA in between two glass office buildings
Gene editing
Gene Editing Patent Landscape Remains ‘Clear as Mud,’ Say Patent Attorneys
The intellectual property landscape for newer gene-editing technologies, like that for CRISPR-Cas9, remains unclear and hard to navigate.
September 4, 2024
 · 
5 min read
 · 
Christoph Schwaiger
Futuristic Cyber Abstracy Eye Background 4K
Business
Roche and Regeneron Square Off in Lucrative Eye Disease Market
Analysts expect the companies’ Vabysmo and Eylea HD to generate a combined $13.2 billion by 2030 in the vascular endothelial growth A therapy market, as healthcare providers and patients switch from older products.
September 4, 2024
 · 
6 min read
 · 
Nick Paul Taylor
Group Of Employees Being Fired By Their Company.
Layoffs
Astellas Gene Therapies to Close Biomanufacturing Facility, Affecting About 100 Employees
Astellas Gene Therapies is closing its San Francisco biomanufacturing facility, shifting gene therapy manufacturing to North Carolina, cutting at least 17 employees and affecting dozens more.
September 3, 2024
 · 
1 min read
 · 
Angela Gabriel
Bayer's factory and office in Berlin
Clinical research
Bayer’s Kidney Disease Drug Kerendia Reduces Cardiovascular Risk by 16%
Bayer’s Kerendia, at the center of a $3 billion sales forecast, reduced the risk of cardiovascular death and heart failure in a Phase III trial.
September 3, 2024
 · 
2 min read
 · 
Annalee Armstrong
Pictured: Boy in a wheelchair looking out the window
Duchenne muscular dystrophy
Dyne Touts ‘Unprecedented’ Dystrophin Expression in Phase I/II DMD Trial for Exon-Skipping Therapy
The highly anticipated results come as the company makes significant changes to its C-suite. Despite the turnover, Dyne said it is looking toward expedited approval pathways for its DMD treatment.
September 3, 2024
 · 
3 min read
 · 
Tristan Manalac
Sanofi's Distribution Center in Quebec, Canada
Multiple sclerosis
Sanofi’s Tolebrutinib Misses Two of Three Late-Stage Multiple Sclerosis Readouts
The BTK inhibitor showed promise in non-relapsing secondary progressive multiple sclerosis but not relapsing MS. The company said it plans to apply for approval for the former “as soon as possible.”
September 3, 2024
 · 
3 min read
 · 
Tristan Manalac
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS